Investment
Features
FeesSafety
Academy
More
Pluang+

Compare 3M Company (MMM) vs Organon & Co. Common Stock (OGN) Price & Performance

3M CompanyTrade
Organon & Co. Common StockTrade

Price performance (Past 24H)

Key statistics

3M Company vs Organon & Co. Common Stock — how do they compare? 3M Company trades at $164.93 (market cap $83.94B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: 3M Company is far larger — about 23.2× Organon & Co. Common Stock's market cap, and 3M Company pays the higher dividend (1.92%). Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and Organon & Co. Common Stock for 0 Days on average.

MMMOGN
Market Cap
$83.94B$3.62B
Volume
2,547,2102,892,999
Sector
IndustrialsHealth
52-Week High
$183.79$13.81
52-Week Low
$141.10$5.70
Typical Hold Time
169 Days0 Days
Enterprise Value
$93.17B$11.04B
Dividend Yield
1.92%0.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

3M Company

3M (MMM) trades at $164.46, up 2.22% with strong recent earnings beats and a bullish analyst consensus price target of $191. The stock shows bearish technical signals but maintains solid fundamentals with 11.9% net margins and 82.77% ROE. Recent Q2 2026 results confirmed operational improvements with 5.4% organic growth and raised guidance, though technical indicators suggest near-term pressure.

The outlook remains positive with manageable litigation risks and strategic focus on high-growth areas like data centers. Key risks include consumer segment weakness and debt levels. Wall Street sentiment is balanced with 48% buy ratings, supporting potential upside from current levels despite technical bearishness.

Organon & Co. Common Stock

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MMM

No sentiment data available yet.

OGN
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About 3M Company

3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.

Read more on MMM →

About Organon & Co. Common Stock

Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.

Read more on OGN →